DEF 14A: Century Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Century Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring proposals for director elections, auditor ratification, and corporate governance amendments.

Summary

• Century Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 9:00 a.m. Eastern Time.
• Stockholders of record as of April 24, 2024, are eligible to vote.
• The meeting will address the election of three Class III directors (Kimberly Blackwell, Joseph Jimenez, and Brent Pfeiffenberger) for terms expiring in 2027.
• Stockholders will also vote on ratifying the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2024 fiscal year.
• An amendment to the company's Second Amended and Restated Certificate of Incorporation to limit officer liability as permitted by Delaware law will be considered.
• Additionally, a proposal to approve adjournment of the Annual Meeting if there are insufficient votes to approve the officer liability amendment will be voted on.
• In April 2024, Century Therapeutics acquired Clade Therapeutics for approximately $35 million upfront, consisting of $15 million in cash and 4,535,333 shares of common stock.
• Also in April 2024, the company completed a $60 million private placement, issuing 15,873,011 shares of common stock at $3.78 per share.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining standard corporate governance matters and recent business activities. The sentiment is neutral to slightly positive due to the company's ongoing efforts to advance its pipeline and strengthen its financial position.

Positives

• The company is taking steps to strengthen its pipeline through the acquisition of Clade Therapeutics.
• A new worldwide license agreement and expansion of existing licenses with FUJIFILM Cellular Dynamics Inc. for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases.
• The company received FDA clearance for the Investigational New Drug application of CNTY-101 in patients with moderate to severe SLE.
• The company is seeking to limit the liability of officers, which may help attract and retain talent.

Risks

• Failure to secure sufficient votes for the proposed amendment to limit officer liability could hinder the company's ability to attract and retain key personnel.
• The company's reliance on third-party collaborations, such as with FUJIFILM Cellular Dynamics Inc., carries inherent risks related to the performance and commitment of these partners.

Future Outlook

The company is focused on advancing its pipeline and platform technology, including through collaborations and acquisitions, to develop cell therapies for cancer and autoimmune/inflammatory diseases.

Management Comments

• 'We are pleased to invite you to attend the 2024 Annual Meeting of Stockholders,' stated Joseph Jimenez, Chairman of the Board.
• Brent Pfeiffenberger, President and Chief Executive Officer, also signed the letter to stockholders.

Industry Context

The company's focus on cell therapies derived from iPSCs aligns with broader industry trends in regenerative medicine and immunotherapy, where there is increasing interest in developing novel treatments for cancer and autoimmune diseases.

Comparison to Industry Standards

• The company's corporate governance structure, including an independent board and various committees, aligns with standard practices for publicly traded biotechnology companies.
• The compensation structure for non-employee directors, including cash retainers and equity grants, is comparable to that of peer companies in the biotechnology industry.
• The company's engagement with stockholders and commitment to ESG initiatives are consistent with growing expectations for corporate responsibility among publicly traded companies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has engaged in transactions with FUJIFILM Cellular Dynamics, Inc. (FCDI), a holder of greater than 5% of the company's securities, including a Master Collaboration Agreement, Manufacturing Agreement, and various license agreements.
• In September 2023, the company and FCDI entered into a worldwide license agreement whereby FCDI will grant non-exclusive licenses to the company for certain patent rights and know-how related to cell differentiation and reprogramming for the development and commercialization of iPSC-derived therapies for the treatment of inflammatory and autoimmune diseases.
• In January 2022, the company and FCDI entered into a letter agreement, which amends the Reprogramming License and the Differentiation License such that (i) the definition of Territory under each of the Reprogramming License and the Differentiation License, for purposes of the sublicenses under the Reprogramming License and the Differentiation License pursuant to the Company’s Research Collaboration and License Agreement with Bristol-Myers Squibb Company, or BMS, dated January 7, 2022, or the Collaboration Agreement, includes Japan, (ii) the licenses granted to the company and its affiliates under the Reprogramming License and the Differentiation License are sublicensable to BMS, including with respect to Japan and (iii) BMS is not subject to grant-back and option provisions under the Reprogramming License.

Stakeholder Impact

• Approval of the proposed amendment to limit officer liability could benefit shareholders by improving the company's ability to attract and retain qualified officers.
• The company's ongoing research and development efforts, including collaborations and acquisitions, have the potential to create value for shareholders and improve treatment options for patients.
• The company's commitment to ESG initiatives and ethical conduct is intended to benefit employees, customers, and the broader community.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the Annual Meeting on June 20, 2024.
• The company will continue to execute its strategy of developing cell therapies for cancer and autoimmune/inflammatory diseases.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Auditor, Officer Liability, Corporate Governance, Stockholders, Century Therapeutics, Clade Therapeutics, Private Placement, FUJIFILM Cellular Dynamics, CNTY-101, iPSCs, Cell Therapies